



## ***Onxeo strengthens its executive management team***

**Paris, (France), Copenhagen, (Denmark), February 10, 2015** - Onxeo SA (Euronext Paris, Nasdaq OMX Copenhagen - ONXEO), an innovative company specialised in orphan oncology treatments, has strengthened its management team with three new senior appointments.

- Elisabeth Carstensen appointed Director of Alliance Management
- Graham Dixon appointed CSO/Head of R&D
- Audrey Legentil-Duméry appointed Director of Human Resources

Judith Greciet, CEO of Onxeo, declared: *“Significantly strengthening our executive management team goes hand in hand with the implementation of our strategic growth plan. Partnerships, R&D and HR are all crucial to accelerating our development and succeeding in our ambition to become a global leader in orphan oncology. Stemming from varied cultural backgrounds and perfectly accustomed to operating in the biotech universe, I am convinced that Elisabeth, Graham and Audrey will greatly contribute to Onxeo’s future development.”*

### ***Elisabeth Carstensen, Director of Alliance Management***

Elisabeth will head a newly created department responsible for coordinating and optimising Onxeo’s relationships with commercial as well as international development partners, significant sources of revenues for the company. Elisabeth Carstensen holds a PhD in organic chemistry and a Master’s degree in chemical engineering from the Technical University of Denmark. Initially responsible for the pharmaceutical development of Belinostat, Elisabeth was lately Director of Business Development and Partnership Management with Topotarget. Elisabeth has also been appointed Director of Onxeo’s Danish operation, ensuring the link between the group’s two entities.

### ***Graham Dixon, CSO/ Head R&D***

Heading the R&D department, Graham Dixon, will be responsible with his teams for leading project development up through commercialisation, strengthening portfolio projects and fostering collaboration with academic experts on promising programmes.

Graham Dixon has a twenty year track record in research and development in pharmaceutical industry, particularly oncology, having held senior management positions within big pharma and biotech. For nearly ten years, Graham worked as Director of R&D with the European biotech Galapagos, accompanying its growth and international development.

Graham Dixon holds a PhD in Biochemistry from the University of Swansea, Wales and an honors degree in Biology from the Universtiy of Bradford. He has numerous patents and scientific publications.

### **Audrey Legentil-Duméry, Director of Human Resources**

A human resources department, headed by Audrey Legentil-Duméry, has been created to support Onxeo's rapid growth and will support international development and talent management, notably in the integration of the French and Danish teams. Previously, Audrey Legentil-Duméry worked as a Senior HR consultant with a Paris-based agency, managing HR on behalf of diverse companies, notably accompanying SME's through periods of growth and transition. Audrey successfully conducted several missions in the pharma and biotech sectors. Audrey holds a Master in Management and Intercultural Communication from CELSA (Sorbonne, Paris).

Pierre Attali, MD, MSc, General Deputy Manager in charge of Strategy and Medical Affairs, is leaving the company to focus on other projects and may continue to collaborate with Onxeo as an advisor.

### **About Onxeo**

Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.

Key products at advanced development stage are:

Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma

Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive preliminary top-line results

Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma

For more information, visit the website [www.onxeo.com](http://www.onxeo.com)

### **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on the company's website ([www.onxeo.com](http://www.onxeo.com))*

### **Contacts :**

Judith Greciet, CEO

[j.greciet@onxeo.com](mailto:j.greciet@onxeo.com)

Nicolas Fellmann, CFO

[n.fellmann@onxeo.com](mailto:n.fellmann@onxeo.com)

+33 1 45 58 76 00

Caroline Carmagnol / Sophie Colin – Alize RP

[onxeo@alizerp.com](mailto:onxeo@alizerp.com)

+33 6 64 18 99 59 / +33 1 44 54 36 62